This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Jun;71(6):e177-e178.

doi: 10.1016/j.eururo.2016.12.013. Epub 2016 Dec 29.

Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8

Ian D Davis¹, Carmel Pezaro², Wanling Xie³, Toni K Choueiri⁴, Daniel Y C Heng⁵

Affiliations

Affiliations

¹ Monash University and Eastern Health, Box Hill, Victoria, Australia. Electronic address: ian.davis@monash.edu.
² Monash University and Eastern Health, Box Hill, Victoria, Australia.
³ Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁴ Dana Farber Cancer Institute, Boston, MA, USA.
⁵ Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.

PMID: 28041718
DOI: 10.1016/j.eururo.2016.12.013

Comment

Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8

Ian D Davis et al. Eur Urol. 2017 Jun.

. 2017 Jun;71(6):e177-e178.

doi: 10.1016/j.eururo.2016.12.013. Epub 2016 Dec 29.

Authors

Ian D Davis¹, Carmel Pezaro², Wanling Xie³, Toni K Choueiri⁴, Daniel Y C Heng⁵

Affiliations

¹ Monash University and Eastern Health, Box Hill, Victoria, Australia. Electronic address: ian.davis@monash.edu.
² Monash University and Eastern Health, Box Hill, Victoria, Australia.
³ Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁴ Dana Farber Cancer Institute, Boston, MA, USA.
⁵ Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.

PMID: 28041718
DOI: 10.1016/j.eururo.2016.12.013

No abstract available

PubMed Disclaimer

Comment on

Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DYC. Davis ID, et al. Eur Urol. 2017 Jun;71(6):970-978. doi: 10.1016/j.eururo.2016.09.047. Epub 2016 Oct 19. Eur Urol. 2017. PMID: 27771126
Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8: The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future.
Iacovelli R, Artibani W, Tortora G. Iacovelli R, et al. Eur Urol. 2017 Jun;71(6):e175-e176. doi: 10.1016/j.eururo.2016.12.012. Epub 2016 Dec 30. Eur Urol. 2017. PMID: 28043706 No abstract available.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information